A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Trial Profile

A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

Active, no longer recruiting
Phase of Trial: Phase I

Latest Information Update: 01 Nov 2017

At a glance

  • Drugs Ivosidenib (Primary)
  • Indications Acute myeloid leukaemia; Haematological malignancies; Myelodysplastic syndromes
  • Focus Adverse reactions; First in man; Therapeutic Use
  • Sponsors Agios Pharmaceuticals
  • Most Recent Events

    • 01 Nov 2017 According to an Agios Pharmaceuticals media release, data from the study will be presented at the 2017 American Society of Hematology (ASH) Annual Meeting and Exposition.
    • 31 May 2017 Status changed from recruiting to active, no longer recruiting.
    • 16 Feb 2017 According to Agios Pharmaceuticals media release, first data from this study will be presented in second half of 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top